BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is a publicly traded the market company. As of July 28, 2026, BBOT trades at $8.74 with a market cap of $706.54M and a P/E ratio of -2.06. BBOT moved +0.00% today. Year to date, BBOT is -30.11%; over the trailing twelve months it is flat. Its 52-week range spans $7.00 to $14.87. Analyst consensus is strong buy with an average price target of $23.50. Rallies surfaces BBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for BBOT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $8.74 |
| Market Cap | $706.54M |
| P/E Ratio | -2.06 |
| EPS | $-4.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.87 |
| 52-Week Low | $7.00 |
| Volume | 1.78K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-134.04M |
| Gross Margin | 0.00% |
8 analysts cover BBOT: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.50.